Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
The metabolism of the new reversible A-selective monoamine oxidase inhibitor amiflamine was studied in relation to polymorphic hydroxylation of debrisoquine in 24 healthy subjects. Amiflamine is metabolized by two consecutive N-demethylations. By construction of urinary recovery ratios analogous to that of debrisoquine/4-hydroxydebrisoquine, correlations between debrisoquine metabolic ratio and amiflamine/demethylated metabolites were significant and consistent within slow and rapid hydroxylators of debrisoquine. It is concluded that debrisoquine hydroxylation and amiflamine N-demethylation might be under common genetic regulation.
D000284:Administration, Oral; D000328:Adult; D001711:Biotransformation; D003647:Debrisoquin / Q000378:metabolism* / Q000652:urine; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D008297:Male; D010627:Phenethylamines / Q000378:metabolism* / Q000652:urine; D011110:Polymorphism, Genetic
D007546:Isoquinolines; D010627:Phenethylamines; C031466:amiflamine; D003647:Debrisoquin